GW Pharmaceuticals to Present at Upcoming Investor Conferences
Justin Gover, GW’s Chief Executive Officer, will present at two upcoming conferences.
Read MoreSelect Page
Posted by Invest In Weed | Nov 22, 2019
Justin Gover, GW’s Chief Executive Officer, will present at two upcoming conferences.
Read MorePosted by Invest In Weed | Nov 10, 2019
Cannabidiol oral solution is recommended as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome.
Read MorePosted by Invest In Weed | Nov 5, 2019
Epidiolex U.S. year to date net sales of $188.0 million, including Q3 net sales of $86.1 million.
Read MorePosted by Invest In Weed | Oct 31, 2019
Stephen Schultz, GW’s Vice President of Investor Relations, will present at two upcoming conferences.
Read MorePosted by Invest In Weed | Sep 24, 2019
GW Pharmaceuticals is the world leader in the development and commercialization of cannabinoid prescription medicines.
Read MoreGet stock alerts, news & related alerts straight to your inbox!